Ovoca Bio (OVB) Competitors GBX 1.53 -0.07 (-4.38%) (As of 12/20/2024 05:05 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitors OVB vs. IMM, EVG, MTFB, OBD, DEST, BSFA, TCF, RENE, SALV, and PYCShould you be buying Ovoca Bio stock or one of its competitors? The main competitors of Ovoca Bio include ImmuPharma (IMM), Evgen Pharma (EVG), Motif Bio (MTFB), Oxford BioDynamics (OBD), Destiny Pharma (DEST), BSF Enterprise (BSFA), Theracryf (TCF), ReNeuron Group (RENE), SalvaRx Group (SALV), and Physiomics (PYC). These companies are all part of the "biotechnology" industry. Ovoca Bio vs. ImmuPharma Evgen Pharma Motif Bio Oxford BioDynamics Destiny Pharma BSF Enterprise Theracryf ReNeuron Group SalvaRx Group Physiomics ImmuPharma (LON:IMM) and Ovoca Bio (LON:OVB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, earnings, valuation, dividends, profitability and media sentiment. Does the MarketBeat Community favor IMM or OVB? ImmuPharma received 249 more outperform votes than Ovoca Bio when rated by MarketBeat users. Likewise, 76.44% of users gave ImmuPharma an outperform vote while only 70.83% of users gave Ovoca Bio an outperform vote. CompanyUnderperformOutperformImmuPharmaOutperform Votes26676.44% Underperform Votes8223.56% Ovoca BioOutperform Votes1770.83% Underperform Votes729.17% Is IMM or OVB more profitable? Ovoca Bio's return on equity of -108.96% beat ImmuPharma's return on equity.Company Net Margins Return on Equity Return on Assets ImmuPharmaN/A -111.20% -43.00% Ovoca Bio N/A -108.96%3.70% Do institutionals and insiders have more ownership in IMM or OVB? 17.4% of ImmuPharma shares are held by institutional investors. 48.3% of ImmuPharma shares are held by insiders. Comparatively, 44.7% of Ovoca Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable earnings and valuation, IMM or OVB? ImmuPharma has higher revenue and earnings than Ovoca Bio. ImmuPharma is trading at a lower price-to-earnings ratio than Ovoca Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuPharma£94.82K52.70-£2.46M-£0.01-120.00Ovoca BioN/AN/A-£3.98M-£0.04-38.25 Which has more volatility and risk, IMM or OVB? ImmuPharma has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Ovoca Bio has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Does the media favor IMM or OVB? In the previous week, Ovoca Bio had 1 more articles in the media than ImmuPharma. MarketBeat recorded 1 mentions for Ovoca Bio and 0 mentions for ImmuPharma. Ovoca Bio's average media sentiment score of 1.22 beat ImmuPharma's score of 0.00 indicating that Ovoca Bio is being referred to more favorably in the news media. Company Overall Sentiment ImmuPharma Neutral Ovoca Bio Positive SummaryImmuPharma beats Ovoca Bio on 8 of the 13 factors compared between the two stocks. Ad Brownstone ResearchMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.I call it my AI Retirement Playbook. I recommend you check it out now. Get Ovoca Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for OVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVB vs. The Competition Export to ExcelMetricOvoca BioBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£1.25M£193.01M£5.10B£1.58BDividend Yield0.83%3.64%4.88%11.58%P/E Ratio-38.25113.2190.831,561.57Price / SalesN/A17,692.741,112.01321,241.47Price / Cash1.0012.3542.0236.80Price / Book0.778.034.772.82Net Income-£3.98M-£20.18M£119.70M£166.53M7 Day Performance-1.29%-1.02%-1.86%-1.71%1 Month Performance-6.13%132.63%11.45%14.78%1 Year Performance78.74%132.00%30.43%24.82% Ovoca Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVBOvoca BioN/AGBX 1.53-4.4%N/A+70.0%£1.25MN/A-38.255Positive NewsGap DownIMMImmuPharmaN/AGBX 1.10+0.9%N/A-25.5%£4.59M£94,819.00-110.2513Gap DownEVGEvgen PharmaN/AGBX 0.80flatN/A-50.0%£3.42MN/A-80.0010MTFBMotif BioN/AGBX 0.50flatN/AN/A£3.28MN/A-0.036OBDOxford BioDynamicsN/AGBX 0.94-11.3%N/A-95.5%£2.93M£176,000.00-16.3045News CoverageGap DownDESTDestiny PharmaN/AGBX 3-30.1%N/A-96.0%£2.87M£135,028.00-50.0024Gap DownHigh Trading VolumeBSFABSF EnterpriseN/AGBX 2.38flatN/A-75.1%£2.45MN/A-125.0012TCFTheracryfN/AGBX 0.53flatN/AN/A£2.24MN/A-51.0010High Trading VolumeRENEReNeuron GroupN/AN/AN/A-7.5%£1.93M£783,000.00-37.502Gap DownSALVSalvaRx GroupN/AGBX 4.50flatN/A+0.0%£1.65M£64.50M0.032Gap UpPYCPhysiomicsN/AGBX 0.80flatN/A-50.7%£1.63M£900,707.00-13.8310 Related Companies and Tools Related Companies IMM Alternatives EVG Alternatives MTFB Alternatives OBD Alternatives DEST Alternatives BSFA Alternatives TCF Alternatives RENE Alternatives SALV Alternatives PYC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:OVB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovoca Bio plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovoca Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OVB Stock Alerts